{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:44:17Z","timestamp":1789767857192,"version":"4.0.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Psoriasis is a worldwide chronic inflammatory skin disease. The treatment of disease is usually designed according to its severity. In this research, RNA-seq was performed on 37 patients with psoriasis treated with guselkumab before and after treatment, and the patients were divided into fast responder and slow responder according to PASI score to analyze the differentially expressed genes (DEGs) between them. Moreover, The biological mechanism of psoriasis was explored by Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, Gene Ontology (GO) analysis, and Gene Set Enrichment Analysis (GSEA) analysis. And then, this protein-protein interaction network was constructed and 17 DEGs including IL-1\u03b2, CXCL8, S100A12 and MMP9 were analyzed by GSVA. DEGs were detected by GO and KEGG analysis of target genes, which were primarily associated with immune response, neutrophil activation, neutrophil degranulation. GSEA reminded that fast responders were mainly involved in low-density neutrophils and abundant NK cells. And the GSVA showed that the DEGs were down-regulated after the early stage of the fast responder and the reverse in the slow responder by GSVA analysis. On the whole, these results indicated that these DEGs may serve as a psoriasis potential diagnostic and predictive biomarkers after been treated by guselkumab.<\/jats:p>","DOI":"10.3389\/fimmu.2022.865875","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T04:50:37Z","timestamp":1653540637000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Based on Gene Expression Analysis: Low-Density Neutrophil Expression Is a Characteristic of the Fast Responders Treated With Guselkumab for Psoriasis"],"prefix":"10.3389","volume":"13","author":[{"given":"Jiajing","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangfeng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis Pathogenesis and Treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis","volume":"2","author":"Greb","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of Psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1159\/000491819","article-title":"Decreased Systemic Levels of Endocan-1 and CXCL16 in Psoriasis Are Restored Following Narrowband Uvb Treatment","volume":"234","author":"Sigurdardottir","year":"2018","journal-title":"Dermatology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601607","article-title":"Cxcl17 Attenuates Imiquimod-Induced Psoriasis-like Skin Inflammation by Recruiting Myeloid-Derived Suppressor Cells and Regulatory T Cells","volume":"198","author":"Oka","year":"2017","journal-title":"J Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/2546161","article-title":"Short-Term Efficacy and Safety of IL-17, Il-12\/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials","volume":"2019","author":"Bai","year":"2019","journal-title":"J Immunol Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and Safety of Guselkumab, an Anti-Interleukin-23 Monoclonal Antibody, Compared With Adalimumab for the Continuous Treatment of Patients With Moderate to Severe Psoriasis: Results From the Phase III, Double-Blinded, Placebo- and Active Comparator-Controlled VOYAGE 1 Trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.01.025","article-title":"Guselkumab (an IL-23-specific mAb) Demonstrates Clinical and Molecular Response in Patients With Moderate-to-Severe Psoriasis","volume":"133","author":"Sofen","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 Signaling Pathway and the Treatment of Psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2174\/1381612826666200311130133","article-title":"Decoding Psoriasis: Integrated Bioinformatics Approach to Understand Hub Genes and Involved Pathways","volume":"26","author":"Choudhary","year":"2020","journal-title":"Curr Pharm Des"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2020.4771","article-title":"Transcriptomic Landscaping of Core Genes and\u00a0Pathways of Mild and Severe Psoriasis Vulgaris","volume":"47","author":"Choudhary","year":"2021","journal-title":"Int J Mol Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.04.035","article-title":"Cross-Disease Transcriptomics: Unique IL-17A Signaling in Psoriasis Lesions and an Autoimmune Pbmc Signature","volume":"136","author":"Swindell","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13993","article-title":"Discovering Novel Hub Genes and Pathways Associated With the Pathogenesis of Psoriasis","volume":"33","author":"Gao","year":"2020","journal-title":"Dermatol Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.19540\/j.cnki.cjcmm.20210703.401","article-title":"Exploration of Active Components and Mechanism of Scutellariae Radix-Phellodendri Chinensis Cortex Drug Pair in Treatment of Psoriasis Based on Network Pharmacology and Molecular Docking","volume":"46","author":"Ma","year":"2021","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.11018","article-title":"Integrated Analysis of Immune-Related Long Noncoding RNAs as Diagnostic Biomarkers in Psoriasis","volume":"9","author":"Fan","year":"2021","journal-title":"PeerJ"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.579625","article-title":"Tre2-Bub2-Cdc16 Family Proteins Based Nomogram Serve as a Promising Prognosis Predicting Model for Melanoma","volume":"10","author":"Tang","year":"2020","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.086611","article-title":"Regulation of CXCL16 Expression and Secretion by Myeloid Cells Is Not Altered Inrheumatoid Arthritis","volume":"68","author":"van Lieshout","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02750.\u00a0eCollection2018","article-title":"Cxcl16\/Cxcr6 Axis Drives Microglia\/Macrophages Phenotype in Physiological Conditions and Plays a Crucial Role in Glioma","volume":"9","author":"Lepore","year":"2018","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.cytogfr.2020.04.004","article-title":"The Protective and Pathogenic Roles of CXCL17 in Human Health and Disease: Potential in Respiratory Medicine","volume":"53","author":"Chore\u00f1o-Parra","year":"2020","journal-title":"Cytokine Growth Factor Rev"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 Studies Comparing Brodalumab With Ustekinumab in Psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.jid.2020.07.012","article-title":"Enhanced Inflammasome Activity in Patients With Psoriasis Promotes Systemic Inflammation","volume":"141","author":"Verma","year":"2021","journal-title":"J Invest Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.865875\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T04:50:41Z","timestamp":1653540641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.865875\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,26]]},"references-count":21,"alternative-id":["10.3389\/fimmu.2022.865875"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.865875","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,26]]},"article-number":"865875"}}